Curcumin derivatives inhibit or modulate beta-amyloid precursor protein metabolism

Neurodegenerative Diseases

Volumn 4, Issue 2-3, 2007, Pages 88-93

  Narlawar, Rajeshwar ^a   Baumann, Karlheinz ^b   Schubenel, Robert ^b   Schmidt, Boris ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alzheimer's disease; Curcumin; Gamma secretase inhibitors; Medicinal chemistry

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; CARBONYL DERIVATIVE; CHOLESTEROL; CURCUMIN; CURCUMINOID; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; OXAZOLE DERIVATIVE; PYRAZOLE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHELATION; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; METAL BINDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RHEUMATOID ARTHRITIS; STEREOISOMERISM;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS;

EID: 34347263391     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000101832     Document Type: Article

References (41)

1. Schmidt B, Braun HA, Narlawar R: Drug development and PET-diagnostics for Alzheimer's disease. Curr Med Chem 2005;12: 1677-1695.
2. Schmidt B: Aspartic proteases involved in Alzheimer's disease. Chembiochem 2003;4: 366-378.
3. 42 generation. J Biol Chem 2003;278:18664-18670.
4. 42 in vivo. J Clin Invest 2003;112:440-449.
5. Beher D, Clarke EE, Wrigley JDJ, Martin ACL, Nadin A, Churcher I, Shearman MS: Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem 2004;279:43419-43426.
6. 42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
7. in 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MMB, Stricker BHC: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
8. Pike CJ, Ramezan-Arab N, Cotman CW: Beta-amyloid neurotoxicity in vitro: evidence of oxidative stress but not protection by antioxidants. J Neurochem 1997;69:1601-1611.
9. Zhou Y, Gopalakrishnan V, Richardson JS: Actions of neurotoxic beta-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. J Neurochem 1996;67:1419-1425.
10. Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K, Hoshino T, Imahori K: Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis: possible role in cholinergic dysfunction in Alzheimer's disease. J Biol Chem 1997;272: 2038-2041.
11. Harkany T, de Jong GI, Soos K, Penke B, Luiten PGM, Gulya K: β-Amyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Brain Res 1995;698:270-274.
12. Gooch MD, Stennett DJ: Molecular basis of Alzheimer's disease. Am J Health Syst Pharm 1996;53:1545-1557;quiz 1603-1544.
13. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A: Stimulation of Aβ42 nicotinic acetylcholine receptors inhibits β-amyloid toxicity. Brain Res 1998;792:331-334.
14. Scott SA, Crutcher KA: Nerve growth factor and Alzheimer's disease. Rev Neurosci 1994; 5:179-211.
15. Seiger A, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A: Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 1993;57:255-561.
16. Mattson MP: Neuroprotective signal transduction: relevance to stroke. Neurosci Biobehav Rev 1997;21:193-206.
17. Pasinetti GM, Aisen PS: Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87:319-324.
18. Grundman M, Corey-Bloom J, Thal LJ: Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J Neural Transm Suppl 1998;53:255-275.
19. Xiao XQ, Zhang HY, Tang XC: Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002;67:30-36.
20. Xiao XQ, Wang R, Tang XC: Huperzine a and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J Neurosci Res 2000; 61:564-569.
21. Kuboyama T, Tohda C, Komatsu K: Withanoside IV and its active metabolite, sominone, attenuate abeta(25-35)-induced neurodegeneration. Eur J Neurosci 2006;23: 1417-1426.
22. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL: A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alz Res 2005;2:131-136.
23. Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle SH, DeKosky ST: Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol 2000;57:824-830.
24. Ammon HP, Safayhi H, Mack T, Sabieraj J: Mechanism of antiinflammatory actions of curcumin and boswellic acids. J Ethnopharmacol 1993;38:113-119.
25. Xu YX, Pindolia KR, Janakiraman N, Chapman RA, Gautam SC: Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopath Mol Hem 1997;11:49-62.
26. Reddy ACP, Lokesh BR: Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem 1992;111:117-124.
27. Sreejayan, Rao MN: Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994;46:1013-1016.
28. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC: Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 1996;26: 54-71.
29. Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ: Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 1989;14:175-185.
30. Sreejayan, Rao MNA: Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997;49:105-107.
31. Kaul S, Krishnakantha TP: Influence of retinol deficiency and curcumin/turmeric feeding on tissue microsomal membrane lipid peroxidation and fatty acids in rats. Mol Cell Biochem 1997;175:43-48.
32. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-5901.
33. Baum L, Ng A: Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alz Dis 2004;6:367-377; discussion 443-369.
34. Soni KB, Kuttan R: Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992;36:273-275.
35. Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, Solyom AM, Timmermann BN: Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 2006;69:351-355.
36. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-244.
37. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
38. Boehm H-J, Schneider G (eds): Virtual Screening for Bioactive Molecules. Weinheim/ New York, Wiley-VCH, 2000.
39. Brockhaus M, Grunberg J, Rohrig S, Loetscher H, Wittenburg N, Baumeister R, Jacobsen H, Haass C: Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport 1998;9:1481-1486.
40. Schmidt B, Baumann S, Narlawar R, Braun HA, Larbig G: Modulators and inhibitors of γ- and β-secretase. Neurodegenerative Dis 2006;03:290-297.
41. Narlawar R, Pérez Revuelta BI, Baumann K, Schubenel R, Haass C, Steiner H, Schmidt B: N-substituted carbazolyloxyacetic acids modulate Alzheimer associated γ-secretase. Bioorg Med Chem Lett 2007;17:176-182.